Express Pharma

Syngene delivers sustained growth in Q4 FY16

2

Revenue grows 31 per cent to Rs 334 crore; EBITA up by 23 per cent to Rs 106 crore

Syngene International has posted Q4FY16 financial results. The company registered a revenue of Rs 334 crore in Q4FY16 as against Rs 254 crore in Q4FY15, EBITDA at Rs 106 crore against Rs 86 crore and profit after tax at Rs 66 crore as against Rs 56 crore.

Jonathan Hunt, Chief Executive Officer, Syngene International said, “We are happy to report excellent revenue growth of 31 per cent during Q4 FY16. This growth has been driven by robust performances within all three of our key business verticals, dedicated R&D centres, discovery services as well as development and manufacturing services. On a full year basis, I am happy to report strong revenue growth of 28 per cent; this momentum, combined with our extensive capital investment plans, puts us ‘on-track’ to achieve our mid-term revenue target for FY 18 and deliver excellent returns for our investors.”

Comments are closed.